Patents Assigned to Glo Pharma, Inc.
  • Peptides and methods for reducing skin pigmentation
    Patent number: 12162956
    Abstract: The present disclosure relates to novel peptide antagonists that inhibit binding of melanocyte stimulating hormone to the melanocortin 1 receptor. The peptide antagonists of the disclosure are useful in cosmetic compositions that prevent or reduce the appearance of skin discoloration caused by pigmentation. The disclosure further relates to cosmetic compositions comprising a peptide antagonist of the disclosure, and methods for their use for preventing or reducing the appearance of skin discoloration in a subject in need thereof.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: December 10, 2024
    Assignee: GLO Pharma, Inc.
    Inventor: Robert A. Love
  • Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods
    Patent number: 11970552
    Abstract: The present invention relates to novel peptide antagonists that inhibit binding of acetylcholine to the active site of the muscle-type nicotinic acetylcholine receptor. The peptide antagonists of the invention are useful in cosmetic compositions that prevent or improve the appearance of skin wrinkles and related skin conditions. The invention further relates to cosmetic and pharmaceutical compositions comprising a peptide antagonist of the invention, and methods for their use.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: April 30, 2024
    Assignee: Glo Pharma, Inc.
    Inventor: Robert A. Love